Osteotech gets FDA approval for Viagraf DBM Paste as bone void filler

By Ted A. Knutson

Washington, Dec. 8 - Osteotech, Inc. said Thursday the Food and Drug Administration has cleared its 510(k) application for Viagraf DBM Paste, one of the company's private label tissue forms, for use as a bone void filler in orthopedic procedures.

In these procedures, Viagraf DBM Paste is intended to be used to fill bone defects in the extremities that may be created surgically or by traumatic injury to the bone.

This is the third approval out of the five 510(k) applications filed with the FDA by Osteotech for its family of DBM products.

Eatontown, N.J.-based Osteotech is a provider of human bone and bone connective tissue for transplantation.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.